Orphan designation: Heterologous human adult liver-derived progenitor cells Treatment of argininosuccinic aciduria, 17/07/2013 Positive

Orphan designation: Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4 Treatment of ovarian cancer, 19/03/2015 Positive

Orphan designation: Heterologous human adult liver-derived progenitor cells Treatment of ornithine-translocase deficiency, 17/07/2013 Positive

PSUSA/00010705/202401

PSUSA/00000170/202401

Human medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Date of authorisation: 14/01/2016, Revision: 19, Status: Authorised

Patient engagement in oncology

Human medicines European public assessment report (EPAR): Oxervate, cenegermin, Date of authorisation: 06/07/2017, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 14, Status: Authorised

Small and medium-sized enterprises info day, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 October 2024, 09:30 (CEST) to 18 October 2024, 16:15 (CEST)